Both ubiquitin ligases FBXW8 and PARK2 are sequestrated into insolubility by ATXN2 polyQ expansions, but only FBXW8 expression is dysregulated

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Halbach, Melanie Vanessa ^a   Stehning, Tanja ^a   Damrath, Ewa ^a   Jendrach, Marina ^a   Şen, Nesli Ece ^b   Başak, A Nazli ^b   Auburger, Georg ^a  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^b BOGAZICI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; PROTEIN ATXN2; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE FBXW8; UBIQUITIN PROTEIN LIGASE PARK2; UNCLASSIFIED DRUG; ATAXIN 2; F BOX PROTEIN; FBXW8 PROTEIN, HUMAN; PARKIN; PEPTIDE; POLYGLUTAMINE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; SKIN FIBROBLAST; SPINOCEREBELLAR DEGENERATION; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; BLOOD; CEREBELLUM; CHEMISTRY; FIBROBLAST; GENE EXPRESSION REGULATION; GENE TARGETING; GENETICS; HELA CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEIN DEGRADATION; PROTEIN TRANSPORT; SOLUBILITY; YOUNG ADULT;

MUS;

ADULT; AGED; ANIMALS; ATAXIN-2; CEREBELLUM; F-BOX PROTEINS; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; GENE KNOCK-IN TECHNIQUES; HELA CELLS; HUMANS; MALE; MICE; MIDDLE AGED; PEPTIDES; PROTEIN TRANSPORT; PROTEOLYSIS; SOLUBILITY; SPINOCEREBELLAR ATAXIAS; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION; YOUNG ADULT;

EID: 84925762475     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121089     Document Type: Article

References (74)

1. Boesch SM, Donnemiller E, Muller J, Seppi K, Weirich-Schwaiger H, Poewe W, et al. Abnormalities of dopaminergic neurotransmission in SCA2: a combined 123I-betaCIT and 123I-IBZM SPECT study. Movement disorders: official journal of the Movement Disorder Society. 2004; 19: 1320-1325.
2. Estrada R, Galarraga J, Orozco G, Nodarse A and Auburger G. Spinocerebellar ataxia 2 (SCA2): morphometric analyses in 11 autopsies. Acta neuropathologica. 1999; 97: 306-310. PMID: 10090679
3. Freund HJ, Barnikol UB, Nolte D, Treuer H, Auburger G, Tass PA, et al. Subthalamic-thalamic DBS in a case with spinocerebellar ataxia type 2 and severe tremor-A unusual clinical benefit. Movement disorders: official journal of the Movement Disorder Society. 2007; 22: 732-735. PMID: 17265523
4. Gierga K, Burk K, Bauer M, Orozco Diaz G, Auburger G, Schultz C, et al. Involvement of the cranial nerves and their nuclei in spinocerebellar ataxia type 2 (SCA2). Acta neuropathologica. 2005; 109: 617-631. PMID: 15906049
5. Gispert S, Kurz A, Waibel S, Bauer P, Liepelt I, Geisen C, et al. The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiology of disease. 2012; 45: 356-361. doi: 10.1016/j.nbd.2011.08.021 PMID: 21889984
6. Rub U, Burk K, Schols L, Brunt ER, de Vos RA, Diaz GO, et al. Damage to the reticulotegmental nucleus of the pons in spinocerebellar ataxia type 1, 2, and 3. Neurology. 2004; 63: 1258-1263. PMID: 15477548
7. Rub U, Del Turco D, Del Tredici K, de Vos RA, Brunt ER, Reifenberger G, et al. Thalamic involvement in a spinocerebellar ataxia type 2 (SCA2) and a spinocerebellar ataxia type 3 (SCA3) patient, and its clinical relevance. Brain: a journal of neurology. 2003; 126: 2257-2272. PMID: 12847080
8. Rub U, Gierga K, Brunt ER, de Vos RA, Bauer M, Schols L, et al. Spinocerebellar ataxias types 2 and 3: degeneration of the pre-cerebellar nuclei isolates the three phylogenetically defined regions of the cerebellum. Journal of neural transmission. 2005; 112: 1523-1545. PMID: 15785863
9. Rub U, Schultz C, Del Tredici K, Gierga K, Reifenberger G, de Vos RA, et al. Anatomically based guidelines for systematic investigation of the central somatosensory system and their application to a spinocerebellar ataxia type 2 (SCA2) patient. Neuropathology and applied neurobiology. 2003; 29: 418-433. PMID: 14507334
10. Velazquez-Perez L, Rodriguez-Labrada R, Canales-Ochoa N, Montero JM, Sanchez-Cruz G, Aguilera-Rodriguez R, et al. Progression of early features of spinocerebellar ataxia type 2 in individuals at risk: a longitudinal study. The Lancet. Neurology. 2014; 13: 482-489. doi: 10.1016/S1474-4422(14)70027-4 PMID: 24657153
11. Lastres-Becker I, Rub U and Auburger G. Spinocerebellar ataxia 2 (SCA2). Cerebellum. 2008; 7: 115-124. doi: 10.1007/s12311-008-0019-y PMID: 18418684
12. Orozco Diaz G, Nodarse Fleites A, Cordoves Sagaz R and Auburger G. Autosomal dominant cerebellar ataxia: clinical analysis of 263 patients from a homogeneous population in Holguin, Cuba. Neurology. 1990; 40: 1369-1375. PMID: 2392220
13. Hernandez A, Magarino C, Gispert S, Santos N, Lunkes A, Orozco G, et al. Genetic mapping of the spinocerebellar ataxia 2 (SCA2) locus on chromosome 12q23-q24.1. Genomics. 1995; 25: 433-435. PMID: 7789976
14. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nature genetics. 1996; 14: 285-291. PMID: 8896557
15. Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, Lopes-Cendes I, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nature genetics. 1996; 14: 269-276. PMID: 8896555
16. Sanpei K, Takano H, Igarashi S, Sato T, Oyake M, Sasaki H, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nature genetics. 1996; 14: 277-284. PMID: 8896556
17. Bauer PO and Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. Journal of neurochemistry. 2009; 110: 1737-1765. doi: 10.1111/j.1471-4159.2009.06302.x PMID: 19650870
18. Orr HT. Polyglutamine neurodegeneration: expanded glutamines enhance native functions. Current opinion in genetics & development. 2012; 22: 251-255.
19. Auburger GW. Spinocerebellar ataxia type 2. Handbook of clinical neurology. 2012; 103: 423-436. doi:10.1016/B978-0-444-51892-7.00026-7 PMID: 21827904
20. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010; 466: 1069-1075. doi: 10.1038/nature09320 PMID: 20740007
21. Yamashita C, Tomiyama H, Funayama M, Inamizu S, Ando M, Li Y, et al. The evaluation of polyglutamine repeats in autosomal dominant Parkinson's disease. Neurobiology of aging. 2014.
22. Charles P, Camuzat A, Benammar N, Sellal F, Destee A, Bonnet AM, et al. Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? Neurology. 2007; 69: 1970-1975. PMID: 17568014
23. Gwinn-Hardy K, Chen JY, Liu HC, Liu TY, Boss M, Seltzer W, et al. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology. 2000; 55: 800-805. PMID: 10993999
24. Lee T, Li YR, Ingre C, Weber M, Grehl T, Gredal O, et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Human molecular genetics. 2011; 20: 1697-1700. doi: 10.1093/hmg/ddr045 PMID: 21292779
25. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997; 277: 1990-1993. PMID: 9302293
26. Lindenberg KS, Yvert G, Muller K and Landwehrmeyer GB. Expression analysis of ataxin-7 mRNA and protein in human brain: evidence for a widespread distribution and focal protein accumulation. Brain pathology. 2000; 10: 385-394. PMID: 10885657
27. Holmberg M, Duyckaerts C, Durr A, Cancel G, Gourfinkel-An I, Damier P, et al. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Human molecular genetics. 1998; 7: 913-918. PMID: 9536097
28. Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 1997; 19: 333-344. PMID: 9292723
29. van de Loo S, Eich F, Nonis D, Auburger G and Nowock J. Ataxin-2 associates with rough endoplasmic reticulum. Experimental neurology. 2009; 215: 110-118. doi: 10.1016/j.expneurol.2008.09.020 PMID: 18973756
30. Huynh DP, Figueroa K, Hoang N and Pulst SM. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nature genetics. 2000; 26: 44-50. PMID: 10973246
31. Duyckaerts C, Durr A, Cancel G and Brice A. Nuclear inclusions in spinocerebellar ataxia type 1. Acta neuropathologica. 1999; 97: 201-207. PMID: 9928833
32. Damrath E, Heck MV, Gispert S, Azizov M, Nowock J, Seifried C, et al. ATXN2-CAG42 sequesters PABPC1 into insolubility and induces FBXW8 in cerebellum of old ataxic knock-in mice. PLoS genetics. 2012; 8: e1002920. doi: 10.1371/journal.pgen.1002920 PMID: 22956915
33. Orr HT and Zoghbi HY. Trinucleotide repeat disorders. Annual review of neuroscience. 2007; 30: 575-621. PMID: 17417937
34. Galvao R, Mendes-Soares L, Camara J, Jaco I and Carmo-Fonseca M. Triplet repeats, RNA secondary structure and toxic gain-of-function models for pathogenesis. Brain research bulletin. 2001; 56: 191-201. PMID: 11719250
35. Lieberman AP, Harmison G, Strand AD, Olson JM and Fischbeck KH. Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Human molecular genetics. 2002; 11: 1967-1976. PMID: 12165558
36. Lim J, Crespo-Barreto J, Jafar-Nejad P, Bowman AB, Richman R, Hill DE, et al. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature. 2008; 452: 713-718. doi: 10.1038/nature06731 PMID: 18337722
37. Satterfield TF and Pallanck LJ. Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes. Human molecular genetics. 2006; 15: 2523-2532. PMID: 16835262
38. Ralser M, Albrecht M, Nonhoff U, Lengauer T, Lehrach H, and Krobitsch S. An integrative approach to gain insights into the cellular function of human ataxin-2. Journal of molecular biology. 2005; 346: 203-214. PMID: 15663938
39. Nonis D, Schmidt MH, van de Loo S, Eich F, Dikic I, Nowock J, et al. Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. Cellular signalling. 2008; 20: 1725-1739. doi: 10.1016/j.cellsig.2008.05.018 PMID: 18602463
40. Nonhoff U, Ralser M, Welzel F, Piccini I, Balzereit D, Yaspo ML, et al. Ataxin-2 interacts with the DEAD/ H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Molecular biology of the cell. 2007; 18: 1385-1396. PMID: 17392519
41. Satterfield TF, Jackson SM and Pallanck LJ. A Drosophila homolog of the polyglutamine disease gene SCA2 is a dosage-sensitive regulator of actin filament formation. Genetics. 2002; 162: 1687-1702. PMID: 12524342
42. McCann C, Holohan EE, Das S, Dervan A, Larkin A, Lee JA, et al. The Ataxin-2 protein is required for microRNA function and synapse-specific long-term olfactory habituation. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108: E655-662. doi: 10.1073/pnas.1107198108 PMID: 21795609
43. Sudhakaran IP, Hillebrand J, Dervan A, Das S, Holohan EE, Hulsmeier J, et al. FMRP and Ataxin-2 function together in long-term olfactory habituation and neuronal translational control. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111: E99-E108. doi: 10.1073/pnas.1309543111 PMID: 24344294
44. Lim C and Allada R. ATAXIN-2 activates PERIOD translation to sustain circadian rhythms in Drosophila. Science. 2013; 340: 875-879. doi: 10.1126/science.1234785 PMID: 23687047
45. Zhang Y, Ling J, Yuan C, Dubruille R and Emery P. A role for Drosophila ATX2 in activation of PER translation and circadian behavior. Science. 2013; 340: 879-882. doi: 10.1126/science.1234746 PMID: 23687048
46. Ho MS, Ou C, Chan YR, Chien CT and Pi H. The utility F-box for protein destruction. Cellular and molecular life sciences: CMLS. 2008; 65: 1977-2000. doi: 10.1007/s00018-008-7592-6 PMID: 18344020
47. Skowyra D, Craig KL, Tyers M, Elledge SJ and Harper JW. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell. 1997; 91: 209-219. PMID: 9346238
48. Benbrook DM and Long A. Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis. Experimental oncology. 2012; 34: 286-297. PMID: 23070014
49. Huynh DP, Nguyen DT, Pulst-Korenberg JB, Brice A and Pulst SM. Parkin is an E3 ubiquitin-ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death. Experimental neurology. 2007; 203: 531-541. PMID: 17097639
50. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998; 392: 605-608. PMID: 9560156
51. Corti O, Lesage S and Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiological reviews. 2011; 91: 1161-1218. doi: 10.1152/physrev.00022.2010 PMID: 22013209
52. von Coelln R, Dawson VL and Dawson TM. Parkin-associated Parkinson's disease. Cell and tissue research. 2004; 318: 175-184. PMID: 15503153
53. Ekholm-Reed S, Goldberg MS, Schlossmacher MG and Reed SI. Parkin-dependent degradation of the F-box protein Fbw7beta promotes neuronal survival in response to oxidative stress by stabilizing Mcl-1. Molecular and cellular biology. 2013; 33: 3627-3643. doi: 10.1128/MCB.00535-13 PMID: 23858059
54. Drost J, Nonis D, Eich F, Leske O, Damrath E, Brunt ER, et al. Ataxin-2 modulates the levels of Grb2 and SRC but not ras signaling. Journal of molecular neuroscience: MN. 2013; 51: 68-81. doi: 10.1007/s12031-012-9949-4 PMID: 23335000
55. Klinkenberg M, Gispert S, Dominguez-Bautista JA, Braun I, Auburger G, and Jendrach M. Restriction of trophic factors and nutrients induces PARKIN expression. Neurogenetics. 2012; 13: 9-21. doi: 10.1007/s10048-011-0303-8 PMID: 22028146
56. Lahut S, Omur O, Uyan O, Agim ZS, Ozoguz A, Parman Y, et al. ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. PloS one. 2012; 7: e42956. doi: 10.1371/journal.pone.0042956 PMID: 22916186
57. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402-408. PMID: 11846609
58. Shibata H, Huynh DP and Pulst SM. A novel protein with RNA-binding motifs interacts with ataxin-2. Human molecular genetics. 2000; 9: 1303-1313. PMID: 10814712
59. Hallen L, Klein H, Stoschek C, Wehrmeyer S, Nonhoff U, Ralser M, et al. The KRAB-containing zinc-finger transcriptional regulator ZBRK1 activates SCA2 gene transcription through direct interaction with its gene product, ataxin-2. Human molecular genetics. 2011; 20: 104-114. doi: 10.1093/hmg/ddq436 PMID: 20926453
60. Affaitati A, de Cristofaro T, Feliciello A and Varrone S. Identification of alternative splicing of spinocerebellar ataxia type 2 gene. Gene. 2001; 267: 89-93. PMID: 11311558
61. Scoles DR, Pflieger LT, Thai KK, Hansen ST, Dansithong W, and Pulst SM. ETS1 regulates the expression of ATXN2. Human molecular genetics. 2012; 21: 5048-5065. doi: 10.1093/hmg/dds349 PMID: 22914732
62. Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, and Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron. 2003; 37: 735-749. PMID: 12628165
63. Auburger G, Gispert S, Lahut S, Omur O, Damrath E, Heck M, et al. 12q24 locus association with type 1 diabetes: SH2B3 or ATXN2? World journal of diabetes. 2014; 5: 316-327. doi: 10.4239/wjd.v5.i3.316 PMID: 24936253
64. Lastres-Becker I, Brodesser S, Lutjohann D, Azizov M, Buchmann J, Hintermann E, et al. Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. Human molecular genetics. 2008; 17: 1465-1481. doi: 10.1093/hmg/ddn035 PMID: 18250099
65. Li XJ and Li S. Proteasomal dysfunction in aging and Huntington disease. Neurobiology of disease. 2011; 43: 4-8. doi: 10.1016/j.nbd.2010.11.018 PMID: 21145396
66. Schipper-Krom S, Juenemann K and Reits EA. The Ubiquitin-Proteasome System in Huntington's Disease: Are Proteasomes Impaired, Initiators of Disease, or Coming to the Rescue? Biochemistry research international. 2012; 2012: 837015. doi: 10.1155/2012/837015 PMID: 23050151
67. Li X, Wang CE, Huang S, Xu X, Li XJ, Li H, et al. Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments. Human molecular genetics. 2010; 19: 2445-2455. doi: 10.1093/hmg/ddq127 PMID: 20354076
68. Schipper-Krom S, Juenemann K, Jansen AH, Wiemhoefer A, van den Nieuwendijk R, Smith DL, et al. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies. FEBS letters. 2014; 588: 151-159. doi: 10.1016/j.febslet.2013.11.023 PMID: 24291262
69. Ortega Z and Lucas JJ. Ubiquitin-proteasome system involvement in Huntington's disease. Frontiers in molecular neuroscience. 2014; 7: 77. doi: 10.3389/fnmol.2014.00077 PMID: 25324717
70. Petroi D, Popova B, Taheri-Talesh N, Irniger S, Shahpasandzadeh H, Zweckstetter M, et al. Aggregate clearance of alpha-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome. The Journal of biological chemistry. 2012; 287: 27567-27579. doi: 10.1074/jbc.M112.361865 PMID: 22722939
71. Carrard G, Bulteau AL, Petropoulos I and Friguet B. Impairment of proteasome structure and function in aging. The international journal of biochemistry & cell biology. 2002; 34: 1461-1474.
72. Yang H, Li JJ, Liu S, Zhao J, Jiang YJ, Song AX, et al. Aggregation of polyglutamine-expanded ataxin-3 sequesters its specific interacting partners into inclusions: implication in a loss-of-function pathology. Scientific reports. 2014; 4: 6410. doi: 10.1038/srep06410 PMID: 25231079
73. Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, Poppe D, et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature. 2011; 480: 543-546. doi: 10.1038/nature10671 PMID: 22113611
74. Scuderi S, La Cognata V, Drago F, Cavallaro S and D'Agata V. Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain. BioMed research international. 2014; 2014: 690796. doi: 10.1155/2014/690796 PMID: 25136611